Eli Lilly and Company
Eli Lillys Push Beyond Weight Loss Gets Another Boost FDA Grants Cancer Drug Orphan Drug Status
finviz·yahoo.com·05/10, 17:51
Lilly Goes Back to Gate Bioscience in a Deal Worth Up to $870 Million
finviz·yahoo.com·05/10, 15:56
Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
finviz·barrons.com·05/10, 15:44
Retatrutide shows promising weight loss results.
1 source·30/09, 19:15·yahoo.com
Eli Lilly's eczema drug gains significant approval.
1 source·30/09, 18:45·yahoo.com
Lilly's lebrikizumab shows promising results for atopic dermatitis.
1 source·30/09, 12:12·finviz.com
Eli Lilly elects Dr. Carolyn R. Bertozzi to board.
1 source·21/11, 21:20·sec.gov
10-Q form submitted!
1 source·30/10, 15:16·sec.gov
Filing of financial results announcement.
1 source·30/10, 11:04·sec.gov
Eli Lilly raised $6.71 billion through notes issuance.
1 source·20/08, 20:18·sec.gov
Eli Lilly Targets Amylin Pathway to Unlock Next Generation Obesity Drug Combinations
finviz·yahoo.com·05/10, 12:42
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
finviz·finviz.com·05/10, 11:50
Stocktwits Pharma Pulse: Roche Faces FDA Decision, Gene-Therapy Stocks Step Into Focus The Weeks Biotech Watchlist
finviz·yahoo.com·05/10, 03:09
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
finviz·finviz.com·02/10, 19:05
Eli Lilly Stock Is Up 7% in 2026 as Its Obesity Pipeline Expands. Heres Where the Stock Could Go by 2030
finviz·yahoo.com·02/10, 15:42
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
finviz·finviz.com·01/10, 11:00
The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind
finviz·wsj.com·01/10, 00:00
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
finviz·finviz.com·30/09, 22:00
Move Aside Retatrutide, Eli Lilly Just Beat Its Next-Gen Obesity Drug
finviz·investors.com·30/09, 16:32
Eli Lilly's weight loss drug combo shed 23% of body weight, topping its own blockbuster
finviz·qz.com·30/09, 16:30